Many short-lived nuclear proteins are targeted for degradation by the ubiquitinproteasome pathway. The role of the nucleus in regulating the turnover of these proteins is not well defined, although many components of the ubiquitin-proteasome system are localized in the nucleus. We have used nucleoplasm from highly purified HeLa nuclei to examine the degradation of a physiological substrate of the ubiquitin-proteasome system (MyoD). In vitro studies using inhibitors of the system demonstrate MyoD is degraded via the ubiquitinproteasome pathway in HeLa nucleoplasm. Purified nucleoplasm in vitro also supports the generation of high molecular mass MyoD-ubiquitin adducts. In addition, in vivo studies using leptomycin B to inhibit nuclear export, demonstrate that MyoD is degraded in HeLa cells by the nuclear ubiquitin-proteasome system.
and Whitelaw, 1999) show that nuclear localization occurs prior to the ultimate ubiquitindependent degradation of these substrates. However, other studies have determined that nuclear export is required for the ubiquitin-dependent degradation of p27 kip1 (Tomoda et al., 1999) , cyclin D1 (Diehl et al., 1998) , p53 (Freedman and Levine, 1998) and IκBα (Rodriguez et al.,
1999) as well as the aryl hydrocarbon receptor (Davarinos and Pollenz, 1999) . These results, which couple nuclear export with degradation of the substrate, suggest that export to the cytoplasmic ubiquitin-proteasome machinery may represent a common route for the degradation of nuclear substrates.
However, ubiquitin-dependent degradation of nuclear substrates in the cytoplasm envisions no role for the proteasome or the ubiquitin activating and conjugating enzymes that are localized to the nucleus. This raises questions about the role of the ubiquitin-proteasome components found in the nucleus and whether the nucleus will support ubiquitin-dependent degradation. To determine if the nucleus and its complement of components are sufficient to support ubiquitin-dependent degradation, we have developed a cell-free system based on highly purified HeLa nucleoplasm. We have evaluated both model substrates and MyoD as a physiological substrate using this system. In addition, we have extended these studies in vivo and taken advantage of the nuclear export inhibitor, leptomycin B (Kudo et al., 1999) .
MyoD is a nuclear basic helix-loop-helix transcription factor that is pivotal in skeletal muscle differentiation (Weintraub et al., 1991) . In addition, MyoD can act as a cell cycle inhibitor during G1 (Crescenzi et al., 1990; Sorrentino et al., 1990) . While the cellular locus for the degradation of MyoD has not been established, in vivo (Song et al., 1998) results now demonstrate that highly purified nucleoplasm will degrade MyoD in a ubiquitinproteasome dependent manner and that in vivo, nuclear export is not required for the degradation of MyoD, indicating that MyoD is degraded by a nuclear ubiquitin-proteasome system.
Experimental Procedures
Cell Culture. HeLa cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM L-glutamine and antibiotics (100 units/ml penicillin G and 100 µg/ml streptomycin) (Life Technologies). The cells were maintained at Transient transfections with MyoD were performed using Lipofectamine according to the manufacturer's instructions (Life Technologies).
Preparation of Extracts.
Rabbit reticulocyte lysate was prepared as previously described (Ciechanover et al., 1978) . Nucleoplasm was obtained from HeLa cells via a procedure that is a modification of those of Dignam et al. (1983) and Blobel and Potter (1966) .
The preparation was monitored microscopically at each step. The HeLa cell pellet was rinsed twice in ice-cold phosphate-buffered saline and once in a hypotonic buffer (10 mM Tris-Cl, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT). The pellet resuspended in the hypotonic buffer was then dounced for 2-3 strokes with a "B" type pestle to ensure a single cell suspension.
Thereafter the cells were swollen via a 45-minute incubation on ice. All buffer volumes were 25 ml/gm pellet (25 ml/liter suspension culture). The swollen cells were then dounced for 35 stokes 6 with an "A" type pestle and the resulting crude nuclei were pelleted at 600g for 10 minutes. The pelleted nuclei were resuspended in 0.25 M sucrose in hypotonic buffer and incubated on ice for 10 minutes. Thereafter, 2.3 M sucrose in hypotonic buffer was added to yield a 1.62 M sucrose solution. The nuclei suspension was layered over a step gradient of 1.80 M and 2.30 M sucrose and centrifuged at 28K rpm for 1 hour in a SW 28 rotor (Beckman). The pellet of nuclei was resuspended in hypotonic buffer and rinsed once by centrifugation in the same buffer. The washed nuclei were then incubated in the hypotonic buffer without MgCl 2 on ice for 15 minutes.
Following sonication, the resulting nucleoplasm was collected after centrifugation at 10,000 rpm for 10 minutes in an Eppendorf microfuge at 4°C and stored at -70°C after rapid freezing in liquid N 2 . When MyoD was used as the substrate, the sonicated nuclei were incubated with 2.5units DNase I/mg protein at room temperature for 20 minutes before the final centrifugation step. This step was necessary for removal of DNA, which is inhibitory in the ubiquitindependent degradation of MyoD (data not shown). Control experiments showed no effect on substrate degradation when DNase I was added to reticulocyte lysate. A typical preparation of nucleoplasm (from 4 L of HeLa cell suspension culture) contained 4-6 mg/ml protein in a total volume of 1-1.5 ml. Protein concentrations were determined by the Bradford method (Bradford, 1976 ) using bovine serum albumin as the standard.
Characterization of HeLa nucleoplasm. Nuclei were evaluated for cytoplasmic protein contamination using both morphological and biochemical criteria. Nuclei were visualized under phase contrast at each step of the preparation and were considered substantially free of cytoplasmic remnants if the nuclear envelope appeared smooth and the nuclei did not clump. The washed nuclei were assayed for lactate dehydrogenase activity as a biochemical marker of cytoplasmic contamination (Stephen et al., 1996) . Total activity was determined using nuclei 7 volume based on total number of nuclei x 0.3 pl/nuclei (Weibel et al., 1969 DTT, 5% glycerol and 2 mM PMSF and nucleic acids were removed by precipitation with 0.3% polyethyleneimine. MyoD was precipitated from the resulting supernatant using 0.6 M ammonium sulfate as described (Thayer and Weintraub, 1993 For the inhibition studies, MG132 (N-carbobenzoxyl-Leu-Leu-Leucinal) (Peptide Institute, Inc.) was diluted to 10 mM in DMSO and was added to the reactions containing the ATP-regenerating system at 20µM. A reaction containing an equal volume of the solvent DMSO was run as a control. Methylated ubiquitin was prepared as previously described (Hershko and Heller, 1985) . Methylated ubiquitin and the ubiquitin K48R mutant (Boston Biochem.) were each prepared as a 25 mg/ml stock in H 2 0 and were added to the degradation reaction containing the ATP-regenerating system at 5, 10 or 15 µg/12.5 µL reaction volume.
ATPγS (Sigma) was prepared as a 0.1 M stock in 10 mM Tris-Cl and the pH was adjusted to 7.0.
Conjugation of MyoD in nuclear extract.
The MyoD cDNA was translated in the presence of 35 S-methionine using a transcription-translation coupled reticulocyte lysate system (Promega). Prior to its addition to the conjugation assay, the labeled substrate-containing mixture was treated with 9 mM N-ethylmaleimide (NEM; Sigma) for 10 minutes at room temperature to inactivate components of the ubiquitin system. The NEM was neutralized with excess (9 mM) NEM. 9 Conjugation assays were performed in a reconstituted cell-free system as described Immunofluorescent localization of MyoD. HeLa cells were transfected with pClneo myoD. 24h later cells were incubated with MG132 or LMB for 3h as described above.
Thereafter, localization of MyoD was determined by indirect immunofluorescence with a polyclonal anti-MyoD antibody (1:500 dilution, Santa Cruz, #sc-760) and the resulting images were photographed under 40X using an Olympus BX60 microscope.
Results

Isolation of purified nuclei and preparation of nucleoplasm.
In an effort to examine the role of the nucleus in the ubiquitin-proteasome dependent degradation of short-lived nuclear proteins, we established a cell free system that supports the ubiquitin-dependent degradation of exogenous protein substrates. This cell-free system is dependent upon highly purified nucleoplasm obtained from HeLa nuclei that were isolated by sucrose density centrifugation. 
ATP-dependent degradation of MyoD in HeLa nucleoplasm.
With this system, we first examined ATP-dependent degradation of lysozyme as a model protein substrate of the ubiquitin-proteasome system (Hershko et al., 1983) . HeLa nucleoplasm served as the source of ubiquitin-proteasome components. All assays were also performed using rabbit reticulocyte lysate in control reactions. After establishing that our cell-free system supports the ATPdependent degradation of lysozyme (data not shown), we next determined if a physiological substrate of the ubiquitin-proteasomal system could be degraded by the nucleoplasm. As seen in 
Ubiquitin conjugation of MyoD in nucleoplasm.
Ubiquitin conjugation assays were performed with isolated nucleoplasm as a direct measurement of the ability of the nuclear ubiquitin system components to support conjugation ( Figure 5 ). 35 S-labeled MyoD is found in higher molecular mass forms typical of ubiquitin conjugate ladders. The MyoD-ubiquitin conjugate ladders occur only in the presence of nuclear extract and are increased by addition of the proteasome inhibitor, ATPγS (Johnston and Cohen, 1981) and ubiquitin aldehyde, an inhibitor of ubiquitin isopeptidases (Hershko and Rose, 1987) . In addition, high molecular mass ubiquitin conjugates accompany nucleoplasm-mediated myoD degradation ( Figure 6 ). These results support our conclusion that the nuclear ubiquitin-proteasome system is responsible for the degradation of MyoD. In the present study, we developed a cell-free system based on HeLa nucleoplasm in order to examine the ability of isolated nucleoplasm to support ubiquitin-dependent degradation.
MyoD is degraded in vivo in
This cell-free system allows for the direct examination of any specific nuclear component of the ubiquitin-proteasome pathway required for the turnover of nuclear substrates. It was essential to ensure that the nucleoplasm is not contaminated with cytoplasmic ubiquitin-proteasome components. We assessed cross-contamination of the cytoplasm and nucleoplasm with protein markers; lactate dehydrogenase activity (cytoplasmic marker) and histone content (nuclear marker). Using this approach, we were able to obtain nucleoplasm that is essentially free of cytoplasmic contamination (i.e. < 0.02%).
We have established that HeLa nucleoplasm contains all the components of the ubiquitinproteasome pathway necessary for degradation of a physiological nuclear substrate, MyoD.
Recent studies have investigated the ubiquitin-dependent degradation of MyoD using both in vivo (Song et al., 1998; Kitzmann et al., 1999) recognition and polyubiquitination are yet to be fully defined. It is possible that turnover of MyoD, the focus of the present study, is regulated differently from other nuclear proteins given the unique requirement for ubiquitination at the N-terminal amino group rather than an internal lysine ). This will be the subject of future studies. 
Figure Legends
